T A B L E O F C O N T E N T S

Main results
We included one trial (13 participants) and identified three ongoing trials that assess RBC transfusion strategies in people with MDS.
The quality of the evidence was very low across different outcomes according to GRADE methodology.
The one included study randomised participants to a restrictive [haemoglobin (Hb) transfusion trigger < 72 g/L, 8 participants] or liberal [Hb trigger < 96 g/L, 5 participants] transfusion policy. There was insufficient evidence to determine a difference in all-cause mortality (1 RCT; 13 participants; RR 0.13, 95% CI 0.01 to 2.32; very low quality evidence). There was insufficient evidence to determine a difference in the number of red blood cell transfusions (1 RCT; 13 participants; 1.8 units per patient per month in the liberal group, compared to 0.8 in the restrictive arm, no standard deviation was reported; very low quality evidence). There were no anaemia-related complications reported (cardiac failure) and no reported effect on activity levels (no statistics provided). The study did not report: mortality due to bleeding/infection/transfusion reactions or iron overload, quality of life, frequency and length of hospital admissions, serious infections (requiring admission to hospital), or serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above).
Authors' conclusions
This review indicates that there is currently a lack of evidence for the recommendation of a particular transfusion strategy for bone marrow failure patients undergoing supportive treatment only. The one RCT included in this review was only published as an abstract and contained only 13 participants. Further randomised trials with robust methodology are required to develop the optimal transfusion strategy for such patients, particularly as the incidence of the main group of bone marrow failure disorders, MDS, rises with an ageing population.
P L A I N L A N G U A G E S U M M A R Y
The optimum transfusion strategy for anaemic patients with bone marrow failure disorders receiving supportive treatment
Review Question
A restrictive transfusion policy involves giving a red blood cell transfusion if the oxygen-carrying capacity of blood (haemoglobin) falls below a certain level. A liberal transfusion policy involves giving a red blood cell transfusion at a higher haemoglobin level.
This review aims to assess whether a restrictive or liberal transfusion policy is superior in terms of death (due to any cause), death due to bleeding, infection, transfusion reactions or iron overload, quality of life, frequency and length of hospital admissions, serious bleeding or infections, and number of red blood cell transfusions required.
Background
The bone marrow is where many types of blood cells are produced. Red blood cells are necessary to bring oxygen to all parts of the body, white blood cells fight against infection, and platelets in the blood help to form clots and prevent bleeding. Bone marrow failure can have different causes and can happen at birth or later in life, and may result in too few of any or all of the three types of blood cells in the body. Too few red blood cells causes a low haemoglobin level, called anaemia, which may result in poor delivery of oxygen to the body. This can cause shortness of breath, tiredness and has a significant impact on quality of life.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Restrictive red blood cell transfusion compared with liberal red blood cell transfusion for patients with myelodysplastic syndrome Patient or population: patients with myelodysplastic syndrome Settings: 2 General and 1 University Hospital Intervention: Restrictive red blood cell transfusion policy (Hb trigger <72 g/L) Comparison: Liberal red blood cell transfusion policy (Hb trigger <96 g/L)
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI)
No of Participants (studies)
Quality of the evidence (GRADE)
Comments
Assumed 
Description of the condition
The bone marrow is the site of production of red cells, white cells and platelets from stem cells (termed collectively as haematopoiesis 
Description of the intervention
Red blood cell transfusions play a central role in the supportive management of patients with long-term bone marrow failure disorders. Currently, there are no clear national guidelines in the UK or elsewhere for the recommendation of a particular transfusion strategy, restrictive (giving a red blood cell transfusion if the haemoglobin (Hb) falls below a certain low threshold) or liberal (giving a red blood cell transfusion at a higher Hb threshold), for such patients. The use of a restrictive transfusion policy is supported by the results of a recent systematic review of 19 randomised controlled trials (RCTs) (Carson 2012). This systematic review included RCTs of both medical and surgical patients of all ages (excluding neonates), but did not include patients with long-term bone marrow failure disorder. Carson 2012 showed that a restrictive transfusion strategy significantly reduced the risk of receiving a transfusion by 39% (risk ratio (RR) 0.61, 95% CI 0.52 to 0.72), without a negative impact on the rate of adverse events (including mortality, myocardial infarction, stroke, pneumonia and thromboembolism). The transfusional requirements and outcomes of the patients included within Carson 2012 may differ from patients with bone marrow failure disorders, and it is therefore less clear whether a restrictive strategy would be beneficial in patients with long-term cytopenias.
Patients with bone marrow failure disorders often present with bi-or tri-lineage cytopenia. There is therefore some concern that concurrent anaemia with thrombocytopenia may increase the risk of bleeding (Valeri 2007). A pilot RCT (60 patients with acute leukaemia or receiving a haematopoietic stem cell transplanta-tion (HSCT), studied the effects of haemoglobin concentration on bleeding risk. It compared those transfused at a haemoglobin threshold of less than 80 g/L to those transfused at a haemoglobin trigger of less than 120 g/L (Webert 2008). This small feasibility study, (conducted to assess whether a larger definitive study would be possible) did not demonstrate a difference in clinically significant bleeding between the study arms, but this may be because the study was not designed to detect a difference. The planned larger definitive study has not yet been performed. The Webert 2008 RCT is included in an ongoing systematic review examining the transfusion needs of patients with haematological malignancies receiving intensive chemotherapy, with or without haematopoietic stem cell transplantation (Butler 2014).
How the intervention might work
A restrictive red blood cell transfusion for patients with chronic bone marrow failure, if feasible, may be advantageous for several reasons. Firstly, the risk of alloimmunisation (i.e. the production of antibodies in response to foreign antigens) to leucocytes in red blood cell transfusions due to the production of both human leukocyte antigen and non-human leukocyte antigen (minor histocompatibility) antibodies may be reduced with a more restrictive transfusion strategy. This may result in a lower risk of graft rejection for those people with aplastic anaemia treated later with an allogeneic bone marrow transplant (Kaminski 1990). Secondly, regular red blood cell transfusion, in the supportive treatment of low-risk MDS, results in raised serum ferritin, which together with transfusion dependence, act as independent adverse risk factors for survival in this group of people (Malcovati 2005). Indeed, serum ferritin levels > 2500 µg/L are associated with an increased transplant-related mortality in those patients with high-risk MDS undergoing myeloablative stem cell transplant (Armand 2011). Thirdly, a restrictive transfusion strategy may also be beneficial when considering the risks of transfusion-transmitted infections, which although very low in the UK (as a result of robust screening programmes), are still a significant problem in those countries with particularly high rates of HIV transmission. This is because there is a time-lag between a person becoming infected with HIV and the HIV test being positive (the window period can be three to six months if only an antibody test is used) (WHO 2009), the inability to test blood due to resource issues (WHO 2015), and ineffective screening of donors (WHO 2015). One further aspect to consider regarding the success of a restrictive versus liberal transfusion programme is the effect on the quality of life in this group of people, data for which are limited. A prospective multicentre trial of 36 elderly low-and intermediate-risk MDS sufferers, treated to a target haemoglobin of > 120 g/L with either erythropoietin (with the addition of Granulocyte-colony stimulating factor (GCSF) if no response) or red blood cell transfusion, showed an improvement in quality of life in terms of fatigue, dyspnoea, constipation and social functioning (Nilsson-Ehle 2011).
In the older population, particularly, where aggressive treatment may be inappropriate, a more supportive approach with regular red blood cell transfusions, primarily for symptomatic relief, may be an attractive alternative for many people with chronic marrow failure disorders. This forms the basis of this systematic review, which aims to compare the effects of a liberal versus restrictive red blood cell transfusion programme in those patients undergoing supportive, rather than active treatment for bone marrow failure, with a particular focus on its impact on quality of life.
Why it is important to do this review
Currently, no clear transfusion strategies are recommended in national guidelines for people with bone marrow failure disorders (Anonymous 2009; Killick 2014; NBA 2012 ). As such, many patients are transfused following local hospital policies, or transfused according to individual patient circumstances, which may result in under-or over-transfusion. Studies of other patient groups, specifically those in critical care and those with acute upper gastrointestinal bleeding have shown possible improved outcomes in terms of survival within the restrictive transfusion arm (Hébert 1999; Villanueva 2013). A restrictive transfusion policy with a lower haemoglobin threshold may be attractive for people who are regularly transfused for several reasons. Despite the very low risks of viral transmission of HIV, hepatitis B and C in the UK, such blood-borne viruses remain considerably higher in other parts of the world. In addition, less frequent red blood cell transfusions would also reduce the number of non-infective adverse events. In 2012, according to the UK Serious Hazards of Transfusion (SHOT) reporting system, haemolytic transfusion reactions were responsible for 19%, and transfusion-related circulatory overload (TACO) for 13% of all pathological transfusion reactions (Bolton-Maggs 2013). Death or severe morbidity occurred in 43% of all cases of TACO reported to SHOT (Bolton-Maggs 2013). However, a transfusion policy that is too restrictive may leave the patient with harmful levels of anaemia, with potential adverse effects on myocardial remodelling and the subsequent development of cardiovascular disease (Pereira  2003) . Therefore, a greater understanding of the safety and benefits of a liberal versus restrictive transfusion policy in patients with bone marrow failure disorders enables the provision of a more tailored red blood cell transfusion strategy for such patients.
O B J E C T I V E S
To assess the efficacy and safety of a restrictive versus liberal red blood cell transfusion strategy for patients with myelodysplasia, acquired aplastic anaemia, and other inherited bone marrow failure disorders.
M E T H O D S Criteria for considering studies for this review
Types of studies
This review included only randomised controlled trials (RCTs), irrespective of language or publication status.
Types of participants
We included all people, irrespective of age, with long-term bone marrow failure disorders that require allogeneic blood transfusion, who are not being actively treated with a haematopoietic stem cell transplant, or intensive chemotherapy.
Types of interventions
We included all allogeneic red blood cell transfusion strategies defined as 'restrictive' and 'liberal'. For individual studies, the restrictive intervention group included people who received an allogeneic red blood cell transfusion only below a definite 'trigger' or 'threshold' haemoglobin. The liberal control group included people that received an allogeneic red blood cell transfusion based on a more generous transfusion strategy, whereby transfusion usually occurs at a higher haemoglobin.
Types of outcome measures
Primary outcomes
• All-cause mortality
• Mortality due to bleeding, infection, transfusion reactions, or iron overload, or both.
Secondary outcomes
• Frequency and length of hospital admissions
• Frequency and length of intensive care admission
• Quality of life (measured using validated scales, for example, EQ-5D, FACT-AN, and EORTC-30)
• Non-fatal serious adverse events classified as:
• serious bleeding (e.g. WHO/CTCAE (The Common Terminology Criteria for Adverse Events) grade 3 (or equivalent) or above);
• adverse transfusion reactions (including, but not limited to transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), blood-group A, B or O incompatibility and transfusion transmitted infection (TTI));
• iron overload (defined by ferritin > 1000 and/or clinical symptoms and/or signs of iron overload); and
• serious infections (infections requiring admission to hospital).
• Blood product requirement • Red cell transfusion requirements (for example, number of units required or number of transfusion episodes) and intervals
• Platelet transfusion requirements (for example, number of pools required, or number of transfusion episodes) and intervals
• Usage of iron chelation therapy
Search methods for identification of studies
The Systematic Review Initiative's Information Specialist (CD) formulated the search strategies in collaboration with the Cochrane Haematological Malignancies Group.
Electronic searches
We searched for RCTs in the following databases.
• Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2015, Issue 4) (Appendix 1)
• We searched for ongoing RCTs to 26th May 2015 in the following databases.
• ClinicalTrials.gov • World Health Organization International Clinical Trials Registry Platform (ICTRP)
We combined searches in MEDLINE with the Cochrane RCT highly sensitive search filter, as detailed in the Cochrane Handbook for Systematic Reviews of Interventions (Lefebvre 2011). We combined searches in EMBASE and CINAHL with the relevant trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN 2010). We did not limit searches by year of publication, language or publication status.
Searching other resources
We also performed handsearches of the reference lists of included studies in order to identify further relevant studies. We made contact with lead authors of relevant studies to identify any unpublished material, missing data or information regarding ongoing studies.
Data collection and analysis
Selection of studies
We selected studies according to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). The Systematic Review Initiative's Information Specialist (CD) screened all search hits for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, two authors (YG, LE) independently screened all the remaining references for relevance against the full eligibility criteria. Full text articles were retrieved for all references for which a decision on eligibility could not be made from title and abstract alone. Study design features were assessed against the inclusion criteria. Additional information was requested from study authors as necessary to assess the eligibility for inclusion of individual studies. The two authors discussed the results of study selection and were able to resolve any discrepancies between themselves. The results of study selection was reported using a PRISMA flow diagram (Moher 2009).
Data extraction and management
As recommended in the Cochrane Handbook for Systematic Reviews of Interventions, two review authors (YG, LE) independently extracted data onto standardised forms and performed a cross-check (Higgins 2011a). The data extraction form was piloted on two included RCTs. The review authors came to a consensus on the required changes. The review authors were not blinded to names of authors, institutions, journals or the study outcomes. The following information was extracted for each study.
1. Source: study identification (ID); report ID; review author ID; date of extraction; ID of author checking extracted data; citation of paper; contact authors details.
2. General study information: publication type; study objectives; funding source; conflict of interest declared; other relevant study publication reviewed.
3. Study details and methods: location; country; setting; number of centres; total study duration; recruitment dates; length of follow-up; power calculation; primary analysis (and definition); stopping rules; method of sequence generation; allocation concealment; blinding (of clinicians, participants and outcome assessors); any concerns regarding bias; inclusion and exclusion criteria; primary outcome(s); secondary outcomes. 2008) ), severity of primary disease, where appropriate (for example, severe, very severe and non-severe aplastic anaemia (Bacigalupo 1988; Camitta 1975)), prognostic classification of primary disease where appropriate (IPSS-R prognostic scoring system for MDS (Greenberg 2012)); additional therapy received; risk of alloimmunisation; baseline haematology laboratory parameters; cofounders reported.
6. Participant flow: total number screened for inclusion; total number recruited; total number excluded; total number allocated to each study arm; total number analysed (for review outcomes); number of allocated patients who received planned treatment; number of drop-outs with reasons (percentage in each arm); protocol violations; missing data.
7. Outcomes: all-cause mortality (undefined and within short-, medium-and long-term periods); mortality due to infection, bleeding, transfusion reactions or iron overload, or both; nonfatal serious adverse events (bleeding, adverse transfusion reactions, iron overload and serious infections); number and volume of red blood cell transfusion units received per patient; interval between red blood cell transfusions, number and volume of platelet doses received per patient; interval between platelet transfusion; frequency and duration of hospital admission, frequency and duration of intensive care admission; usage of iron chelation therapy; quality of life.
Assessment of risk of bias in included studies
We assessed all RCTs for risk of bias using the Cochrane 'Risk of bias' criteria, as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b). Two review authors (YG, LE) worked independently to assess each element of potential bias listed below as 'high', 'low' or 'unclear' risk of bias. A brief description of the judgement statements upon which the review authors have assessed potential bias is reported in the 'Characteristics of included studies' table. A consensus on the degree of risk of bias was met through comparison of the review author's statements without the need for consultation with a third author. We did not use the 'Risk of bias' assessment to explore statistical heterogeneity in each included study and to perform sensitivity analyses because there was only one included study. We used the Cochrane tool for assessing risk of bias (low, high or unclear risk) in the following areas (Higgins 2011c). .
• Selection bias: (random sequence generation and allocation concealment).
• Performance bias: (blinding of participants and personnel).
• Detection bias: (blinding of outcome assessment).
• Attrition bias: (incomplete outcome data).
• Reporting bias: (selective reporting).
• Other bias.
Measures of treatment effect
For continuous outcomes we recorded the mean, standard deviation, and total number of participants in both the treatment and control groups. For dichotomous outcomes we recorded the number of events and the total number of participants in both the treatment and control groups. If data allowed, we undertook quantitative assessments using Review Manager 5 (RevMan 2014).
We had planned to analyse continuous outcomes using the same scale, using the mean difference (MD) with 95% confidence intervals (CIs), and for continuous outcomes measured with different scales using the standard mean difference (SMD), however no meta-analyses were performed. We had planned to report hazard ratios (HRs) if available, for mortality data, however no HRs were reported, and we were unable to estimate the HR using the available data and a purpose built method based on the Parmar and Tierney tool (Parmar 1998; Tierney 2007). We reported risk ratios (RRs) with a 95% CI (for mortality, as HRs were not available). We did not use the Peto Odds Ratio (OR) method for analysis (Deeks 2011) because the number of observed events was not small (< 5% of sample per group). We did not report the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) with CIs because there was insufficient evidence to determine a difference in any of the reported outcomes. We provided a descriptive summary of the available data when the data could not be presented in any other format.
Unit of analysis issues
We did not encounter any specific unit of analysis issues associated with cluster-randomised trials, cross-over studies, and multiple observations for the same outcome. Should any studies of these designs have arisen, we had planned to treat these in accordance with the advice given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011d).
Dealing with missing data
We contacted the authors of the four eligible studies to obtain further information, however no further data could be provided.
Assessment of heterogeneity
We did not perform an assessment of heterogeneity as it was not possible to perform meta-analysis due to only one study satisfying the eligibility criteria for inclusion.
Assessment of reporting biases
We were not able to perform an assessment of reporting bias due to lack of both outcome data and meta-analysis (Lau 2006; Sterne 2011).
Data synthesis
We performed analyses according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions using aggregated data for analysis (Deeks 2011). For statistical analysis, we entered data into Review Manager 5 software (RevMan 2014). One review author (YG) entered the data and a second author (LE) then checked for accuracy. Meta-analysis was not possible because this review included only one study. We therefore provided a descriptive summary of the available information.
Summary of findings
We used the GRADE system to build a 'Summary of findings' 
Subgroup analysis and investigation of heterogeneity
We had planned to conduct the following subgroup analyses.
• Subgroup analysis for all bone marrow failure disorders.
• Type of bone marrow failure disorders (myelodysplastic syndrome (MDS), aplastic anaemia, congenital bone marrow failure disorder);
• Paediatric (< 18 years) versus adult (18 to 65 years) versus elderly (> 65 years).
• Subgroup analysis for individual disorders.
• High-risk MDS versus low-risk MDS (as defined by IPSS-R prognostic risk categories/scores);
• Acquired aplastic anaemia versus inherited childhood bone marrow failure disorder.
However, subgroup analysis was not possible due to the lack of outcome data.
Sensitivity analysis
We planned to assess the robustness of our findings by performing the following sensitivity analyses where appropriate.
• Including only those studies with a 'low risk' of bias (for example, RCTs with methods assessed as low risk for random sequence generation and concealment of treatment allocation).
• Including only those studies with less than a 20% drop out rate.
Sensitivity analysis was not possible as no meta-analysis was performed.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies
The main search was performed on 26th May 2015. A total of 3745 records were identified in the initial search, from which 2286 duplicates were removed, reducing the total records to 1459. From this, one author (CD) screened and removed 346 records that were clearly irrelevant (e.g. non-human). The remaining 1113 records were screened independently by two authors (YG, LE) against the inclusion criteria, from which 1091 records were excluded as ineligible, often due to incorrect study design or wrong comparisons. The remaining 21 records were obtained as full text articles, from which four studies were excluded as ineligible (two studies included transplant patients only, and two other studies analysed ineligible interventions). There remained a total of four studies eligible for inclusion (one completed and three ongoing studies).
Included studies
See Characteristics of included studies for full details of the study. Four studies met the inclusion criteria for the review but three of these studies are ongoing (ISRCTN26088319; NCT02099669; NTR2684) so are not eligible for inclusion in this review. One completed study (Temple 2004) was included within this review.
Study Design
The Temple study (Temple 2004) was a parallel-group multi-centre (two general and one university hospital), single-blinded RCT conducted in the Netherlands. This study has only been published as an abstract. The trial ran from July 2002 to June 2004.
Setting
The study was conducted in Holland with patients recruited from two general and one university hospital.
Participants
The study had originally planned to recruit 200 patients, however due to difficulties in recruitment, only 15 Myelodysplastic syndrome (MDS) patients were included in the study; four were classified as having refractory anaemia, five with refractory anaemia with ringed sideroblasts, four with refractory cytopenia with multilineage dysplasia, one with refractory anaemia with excess of blasts, and one with chronic myelomonocytic leukaemia. From this, 13 patients were randomised to either a restrictive or liberal transfusion policy.
Intervention and Comparator
This study compared a restrictive transfusion policy (haemoglobin transfusion trigger < 72 g/L) with a liberal transfusion trigger (haemoglobin < 96 g/L) in terms of red blood cell usage and quality of life.
Co-interventions
There were no co-interventions in this study.
Outcomes
Quality of life was not reported, however there were no anaemiarelated complications (e.g. cardiac failure and cerebrovascular ischaemia) or decrease in activity performance.
Funding Sources
The study was funded by two government agencies and one charity.
Ongoing Studies
There are three ongoing clinical trials (NTR2684, NCT02099669 and ISRCTN26088319). Please see Characteristics of ongoing studies for further details.
NTR2684
Trial NTR2684 is a parallel-group open-label RCT that started on 1 January 2011, with a planned closing date of 31 December 2012. However, this study has not been completed and is not actively recruiting participants (e-mail correspondence with Dr Slomp). This trial is being conducted in the Netherlands. NTR2684 plans to recruit 100 adults with myelodysplastic syndrome, chronic myelofibrosis and myeloproliferative conditions needing chronic transfusions as supportive care. It will compare transfusion with one unit of packed red blood cells versus two units of packed red blood cells if haemoglobin falls below 5.0mmol/l.
NCT02099669
Trial NCT02099669 is a parallel-group open-label RCT planned to start in March 2014 with an estimated completion date of February 2016. The trial is running in Canada. NCT02099669 plans to recruit 30 transfusion-dependent adults with myelodysplastic syndrome. It plans to compare a liberal transfusion strategy (maintaining Hb level between 110 g/L and 120 g/L) versus a restrictive transfusion strategy (maintaining Hb level between 85 g/L and 100 g/L).
ISRCTN26088319
Trial ISRCTN26088319 is a parallel-group multicentre RCT conducted in the UK. The trial opened on 10th November 2014, and the recruitment end date is planned for 30th December 2016. ISRCTN26088319 plans to recruit 38 transfusion-dependent adults with myelodysplastic syndrome (to include non-proliferative chronic myelomonocytic leukaemia (CMML) and other myeloproliferative/myelodysplastic (MPD/MDS) overlap syndromes). It will compare a restrictive transfusion strategy (maintain Hb level between 85 g/L and 100 g/L) versus liberal transfusion strategy (maintain Hb above 100 g/L).
Excluded studies
See Characteristics of excluded studies for full details of the studies. A total of 14 full-text articles were excluded. Of these:
• • four were RCT's comparing interventions or participants that did not meet our inclusion criteria:
• two only recruited patients undergoing a haematopoietic stem cell transplant (Robitaille 2013; Tay 2011)
• two compared different interventions that were not relevant to this review (Chia 2010; Efficace 2013).
Risk of bias in included studies
Only one study was included in this review, and it was only published as an abstract, therefore it was not possible to assess risk of bias in the majority of cases due to a lack of information provided in the study abstract. Please see Figure 2 for a visual representation of the risk of bias in the included study. See the Characteristics of included studies section 'Risk of bias' table for further information about the bias identified within the trial.
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included
study.
Allocation
The risk of bias was unclear and could not be assessed due to a lack of information provided by the study abstract.
Blinding
There was an unclear risk of performance bias as the patients were blinded to their Hb value during the study period, but the method of blinding and confirmation that blinding had been achieved during the study was not reported. It was also not reported whether clinical staff were blinded to the intervention. The risk of detection bias was unclear and could not be assessed due to lack of information provided by the study abstract.
Incomplete outcome data
Losses to follow up were reported in the study abstract. Following randomisation, a total of two patients died in the liberal group, and one patient withdrew consent in the restrictive arm. However, it is not clear if and how these patient data were included in the final analysis of mean Hb, amount of transfused red cells and anaemia related complications. The mean follow up period in the liberal group was 6.2 months (inclusive run in period) and 7.4 months for the restrictive group. Patients were planned to be followed up for 12 months (excluding run in period of three months).The risk of bias was therefore high.
There was evidence of a high risk of reporting bias in this study abstract as a number of primary and secondary outcomes were not reported, despite intention to collect, as described in the trial registration. The following planned outcomes were not reported. Primary outcome measure. 
Other potential sources of bias
The planned study recruitment for the Temple 2004 was 200 patients, however the study was stopped early due to poor recruitment. The numbers of participants in each study arm was very small, with only eight patients in the restrictive arm and five patients in the liberal arm.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
We were not able to categorise all outcomes according to short-, medium-, and long-term outcomes due to the limited data available. We were also not able to report the exact definition of these time frames over time periods that were common to as many studies as possible (for example, up to 30 days, one to six months, and greater than six months), again due to limited data.
All-cause mortality
In the Temple 2004 study, during the run-in period of three months when all 15 patients included in the study were transfused with Hb trigger < 96 g/L, there were two patient deaths prior to randomisation. The cause of death was not reported. Post randomisation, two patients out of five allocated to the liberal transfusion policy died. No patient deaths were reported in the restrictive arm. Again, the cause of death was not reported. There was insufficient evidence to determine a difference in all-cause mortality between a restrictive [haemoglobin (Hb) transfusion trigger < 72 g/L, eight participants] or a liberal [Hb trigger < 96 g/L, five participants] transfusion policy (RR 0.13, 95% CI 0.01 to 2.32; very low quality evidence). (Figure 3) . 
Mortality due to bleeding, infection, transfusion reactions, or iron overload
We were unable to report on mortality due to bleeding, infection, transfusion reactions, or iron overload, or both, due to lack of available data. No studies reported this outcome.
Secondary outcomes
The only secondary outcome we were able to report on was red blood cell transfusion requirements in terms of number of units required, but not number of transfusion episodes or intervals due to lack of available data. We were not able to report on any of the other secondary outcomes.
Frequency and length of hospital admissions
No studies reported this outcome.
Frequency and length of intensive care admission
Quality of life (measured using validated scales, for example, EQ-5D, FACT-AN, and EORTC-30)
In the Temple 2004 study fatigue measured using the Multidimensional Fatigue Index 20 ( MVI20 ) was reported as the primary outcome measure in the clinical trial register for this study. The Short Form 36 (SF-36) andEuroQol 5D were reported as sec-ondary outcomes. However, no results were given for these outcomes in the published abstract report.
Non-fatal serious adverse events classified as:
Serious bleeding (e.g. WHO / CTCAE grade 3 or above or equivalent)
Adverse transfusion reactions (including, but not limited to transfusion-related acute lung injury (TRALI), transfusionassociated circulatory overload (TACO), ABO mismatched transfusions and transfusion transmitted infection (TTI))
Iron overload (defined by ferritin > 1000 or clinical symptoms, or signs of iron overload, or all three)
Serious infections (infections requiring admission to hospital)
Blood product requirement
Red blood cell transfusion requirements (for example, number of units required or number of transfusion episodes) and intervals
In the Temple 2004 study there was insufficient evidence to determine a difference in the amount of red blood cell transfusions (1.8 units per patient per month in the liberal group, compared to 0.8 in the restrictive arm, no standard deviation was reported; very low quality evidence).
Platelet transfusion requirements (for example, number of pools required, or number of transfusion episodes) and intervals
Usage of iron chelation therapy
D I S C U S S I O N
Summary of main results
A total of four RCTs met the inclusion criteria, however three studies (ISRCTN26088319, NCT02099669, NTR2684) are ongoing, with only one study (Temple 2004) being completed. This study randomised a total of 13 patients with MDS to a liberal or restrictive transfusion strategy. There was insufficient evidence to determine a difference in all-cause mortality (RR 0.13, 95% CI 0.01 to 2.32). There was insufficient evidence to determine a difference in the number of red blood cell transfusions. No anaemiarelated complications were reported. No studies reported on mortality secondary to bleeding, infection, transfusion reactions or iron overload; quality of life; frequency and length of hospital admissions; serious infections (requiring admission to hospital); or serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above).
Overall completeness and applicability of evidence
Conclusions drawn using the data extracted from this systematic review are very limited by the inclusion of only one RCT (Temple 2004) with a small number of participants. The Temple 2004 study reported on only one of this review's primary outcomes, allcause mortality, and on one secondary outcome, red blood cell transfusion requirements. Due to the small numbers of participants in this study, there is insufficient evidence at present to draw any firm conclusions. The Temple 2004 study did not report on several of this review's outcomes, including mortality due to bleeding, infection, transfusion reactions, or iron overload, or both; frequency and length of hospital admissions; frequency and length of intensive care admission; serious bleeding; adverse transfusion reactions; iron overload; serious infections; platelet transfusion requirements; and usage of iron chelation therapy. This highlights the ongoing lack of data for these outcomes. Nevertheless, we identified three ongoing studies ( ISRCTN26088319, NCT02099669, NTR2684) randomising participants to either a liberal or restrictive transfusion strategy with aims to measure many of the above outcomes. When complete, the results of all four RCTs taken together should provide more meaningful conclusions. These ongoing studies plan to complete recruitment by December 2016.
Quality of the evidence
The Temple 2004 study was published only in abstract form, and assessment of selection bias was not possible due to lack of information. With regards to blinding, the risk of bias here is unclear, as although the participants were blinded to their haemoglobin result, the method and assessment of blinding was not reported.
Blinding of clinical staff to the intervention was also not reported.
There was high attrition bias as it was not clear if and how the patients were lost to follow up (two deaths in the liberal group and one patient withdrew consent in the restrictive arm) however follow-up was much shorter than planned (mean 6.2 to 7.4 months versus planned 15 months). Reporting bias risk was high due to a number of both primary and secondary outcomes not reported, despite intention to collect, as detailed in the trial registration. Finally, other risks of bias include the trial stopping earlier than planned due to poor recruitment, and a discrepancy noted between two published versions of the study abstract with regards to the dates reported for the recruitment timeline. It is not clear which is the correct recruitment time period. Overall, taking the above into account, high risk of bias exists for this study, and the quality of evidence is therefore very low.
Overall the quality of the evidence was rated as very low across different outcomes according to GRADE methodology (Schünemann 2011b) (Summary of findings for the main comparison). This was due to the study being at high risk of bias, and the outcome estimates being imprecise. Two outcomes were considered very low grade quality evidence according to GRADE methodology due to the very serious risk of bias of the included studies (see above) and the serious imprecision of the estimates.
• All-cause mortality.
• Red blood cell transfusion requirements.
The reason for the imprecision is because of the small number of participants within the trial and the low number of events. None of the other outcomes of this review were reported.
Potential biases in the review process
To our knowledge, our review process is free from bias. We conducted a comprehensive search; searching data sources (including multiple databases, and clinical trial registries) to ensure that all relevant trials would be captured. There were no restrictions made for the language in which the paper was originally published. The relevance of each paper identified was carefully assessed and all screening and data extractions were performed in duplicate. We pre-specified all outcomes and subgroups prior to analysis. Only one study was included in this review so no meta-analyses could be performed, and publication bias by the use of a funnel plot could not be performed.
Agreements and disagreements with other studies or reviews
To our knowledge, there are no other systematic reviews that report on this topic. None of the systematic reviews excluded within this review (Brereton 2011; Caocci 2009; Clissa 2011; Pinchon 2009; Platzbecker 2012) included studies that compared a restrictive versus liberal red cell transfusion strategy.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The results of this systematic review indicate that there is currently very limited evidence available to recommend a particular transfusion strategy for patients with bone marrow failure requiring supportive treatment. The only data available are extracted from one RCT. This trial recruited very small numbers of patients (13 participants) and it is currently not possible to recommend one transfusion strategy over another for the supportive management of patients with bone marrow failure.
Implications for research
As the incidence of MDS rises with an ageing population, many of whom are unable to tolerate curative therapy, further clinical trials with robust methodology are now required to develop the optimal transfusion strategy for such people. 
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
D A T A A N D A N A L Y S E S
D E C L A R A T I O N S O F I N T E R E S T
Yisu Gu: none known.
Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant -Safe and Appropriate Use of Blood Components.
Carolyn Doree: none known.
Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant -Safe and Appropriate Use of Blood Components.
Paresh Vyas: none known.
S O U R C E S O F S U P P O R T
Internal sources
• 
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
There are several differences between the protocol (Gu 2015) and this review due to lack of data. We were not able to categorise all outcomes according to short-, medium-, and long-term outcomes due to lack of outcome data available.
We were not able to report on the primary outcome of mortality due to bleeding, infection, transfusion reactions, or iron overload, or both, due to lack of outcome data available.
We were not able to report on the following secondary outcomes due to lack of data available.
• Frequency and length of hospital admissions.
• Frequency and length of intensive care admissions.
• serious bleeding;
• adverse transfusion reactions;
• iron overload;
• serious infections.
• Blood product requirement:
• Platelet transfusion requirements (for example, number of pools required, or number of transfusion episodes) and intervals.
• Usage of iron chelation therapy. 
